Management of Chinese patients with type 2 diabetes, 1998–2006: the Diabcare-China surveys

References

• Li G, Hu Y, Pan X. Prevalence and incidence of NIDDM in Daqing City. Chin Med J (Engl) 1996;109:599-02
   PubMed Web of Science ®Google Scholar
• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31
   PubMed Web of Science ®Google Scholar
• Riddle M. A symposium: combining sulfonylureas and other oral agents. Am J Med 2000;108 (6A):15-22S
   Google Scholar
• World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington 2002
   Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
   PubMed Web of Science ®Google Scholar
• Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care 1997;20:1664-9
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Keen H, et al., eds. International Textbook of Diabetes Mellitus, 2nd edn, Chicester, UK: John Wiley, 2004: Chapter 70
   Google Scholar
• Anderson Rj, Freedland KE, Clouse RE, et al. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-78
   PubMed Web of Science ®Google Scholar
• Bech P, Moses R, Gomis R. The effect of prandial glucose regulation with repaglinide on treatment satisfaction, well-being and health status in patients with pharmacology-naïve type 2 diabetes: a placebo-controlled, multicentre study. Qual Life Res 2003;12:413-25
   PubMed Web of Science ®Google Scholar
• Shea S, Skovlund S, Bech P, et al. Routine assessment of psychological well-being in people with diabetes – validation of the WHO-5 Well-being Index in six countries. Diabetologia 2003;46 (Suppl 2):A88[no 245]
   Web of Science ®Google Scholar
• Richard RR, Mark P, Linda MS; on behalf of the International DAWN Advisory Panel: Health Care and patient-reported outcomes: Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care 2006;29:1249-55
   PubMed Web of Science ®Google Scholar
• Soren ES, Peyrot M; on behalf of the DAWN International Advisory Panel. The Diabetes, Attitudes, Wishes, and Needs (DAWN) Program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum 2005;18:136-42
   Google Scholar
• Alberti G. The DAWN (Diabetes Attitudes, Wishes and Needs) Study. Pract Diab Int 2002;19:22-24a
   Google Scholar
• Korykowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes 2002;26 (Suppl 3):S18-24
   Web of Science ®Google Scholar
• American Diabetes Association: Standards of medical care in diabetes – 2006. Diabetes Care 2006;29:S4-42
   PubMed Web of Science ®Google Scholar
• Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-62
   PubMed Web of Science ®Google Scholar
• Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clinical Therapeutics 2006;28:1712-25
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
   PubMed Web of Science ®Google Scholar
• Delorme S, Chiasson JL. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr Opin Pharmacol 2005;5:184-9
   PubMed Web of Science ®Google Scholar
• Wright A, Burden AC, Paisey RB, et al. Sulfonylurea Inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective diabetes Study (UKPDS 57). Diabetes Care 2002;25 (2):330-6
   PubMed Web of Science ®Google Scholar
• IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005
   Google Scholar
• Type 2 diabetes practical targets and treatments, 3rd edn. Asia-Pacific Type 2 diabetes Policy Group. Health Communications Australia Pty Limited and In Vivo Communication Pty Limited, Sydney, Australia, 2002
   Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes. Diabetes Care 2004;27:S15-35
   PubMedGoogle Scholar
• European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30
   PubMed Web of Science ®Google Scholar
• The Oxford International Diabetes Summit: Implications of the DAWN study. Pract Diab Int 2002;19:187-92
   Google Scholar